Liraglutide and semaglutide improve cardiovascular and renal outcomes across most BMI categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials

被引：0
|
作者：
Verma, S. [1 ,2 ]
Bain, S. C. [3 ]
Bhatt, D. L. [4 ,5 ]
Leiter, L. A. [1 ,2 ]
Mazer, C. D. [1 ,2 ]
McGuire, D. K. [6 ]
Pratley, R. [7 ]
Zinman, B. [8 ]
Lindberg, S. [9 ]
Rasmussen, S. [9 ]
Vrazic, H. [9 ]
Buse, J. B. [10 ]
机构：
[1] St Michaels Hosp, Toronto, ON, Canada
[2] Univ Toronto, Toronto, ON, Canada
[3] Swansea Univ, Inst Life Sci, Swansea, W Glam, Wales
[4] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA
[5] Harvard Med Sch, Boston, MA 02115 USA
[6] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[7] AdventHlth Translat Res Inst Metab & Diabet, Orlando, FL USA
[8] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[9] Novo Nordisk AS, Soborg, Denmark
[10] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1164
引用
收藏
页码：S560 / S560
页数：1
相关论文
共 50 条
  • [1] Liraglutide and semaglutide improve cardiovascular and renal outcomes across baseline BP categories: analysis of LEADER and SUSTAIN 6
    Leiter, L. A.
    Bain, S. C.
    Bhatt, D. L.
    Buse, J. B.
    Mazer, C. D.
    Pratley, R.
    Lindberg, S.
    Rasmussen, S.
    Vrazic, H.
    Verma, S.
    [J]. DIABETOLOGIA, 2019, 62 : S364 - S365
  • [2] The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Most Body Mass Index Categories in Type 2 Diabetes: Results of the LEADER and SUSTAIN 6 Trials
    Verma, Subodh
    Bain, Stephen
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    Mazer, C. David
    McGuire, Darren K.
    Pratley, Richard
    Zinman, Bernard
    Lindberg, Sore
    Rasmussen, Soren
    Vrazic, Hrvoje
    Buse, John
    [J]. CIRCULATION, 2018, 138
  • [3] The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: Analysis of LEADER and SUSTAIN 6
    Leiter, Lawrence A.
    Bain, Stephen
    Bhatt, Deepak L.
    Buse, John
    Mazer, C. David
    Pratley, Richard
    Lindberg, Soren
    Rasmussen, Soren
    Vrazic, Hrvoje
    Verma, Subodh
    [J]. CIRCULATION, 2018, 138
  • [4] The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials
    Leiter, Lawrence A.
    Bain, Stephen C.
    Bhatt, Deepak L.
    Buse, John B.
    Mazer, C. David
    Pratley, Richard E.
    Rasmussen, Soren
    Ripa, Maria Sejersten
    Vrazic, Hrvoje
    Verma, Subodh
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (09): : 1690 - 1695
  • [5] Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials
    Strain, W. D.
    Holst, A. G.
    Rasmussen, S.
    Saevereid, H. A.
    James, M. A.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S130 - S131
  • [6] Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials
    Strain, W. D.
    Holst, A. G.
    Rasmussen, S.
    Saevereid, H. A.
    James, M. A.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 2424 - 2424
  • [7] Liraglutide and renal outcomes in Type 2 diabetes: results of the 'Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results' (LEADER) trial
    Poulter, N.
    Mann, J. F. E.
    Brown-Frandsen, K.
    Daniels, G. H.
    Kristensen, P.
    Nauck, M. A.
    Nissen, S. E.
    Pocock, S.
    Buse, J. B.
    Petrie, J.
    [J]. DIABETIC MEDICINE, 2017, 34 : 23 - 24
  • [8] Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER trial
    Mann, Johannes
    Nauck, Michael
    Jacob, Stephan
    Ludemann, Jorg
    Brown-Frandsen, Kirstine
    Rieck, Markus
    Daniels, Gilbert H.
    Kristensen, Peter
    Nissen, Steven E.
    Pocock, Stuart
    Poulter, Neil R.
    Ravn, Lasse S.
    Rasmussen, Soren
    Steinberg, William M.
    Stockner, Mette
    Zinman, Bernard
    Bergenstal, Richard M.
    Baeres, Florian M. M.
    Marso, Steve P.
    Buse, John B.
    [J]. INTERNIST, 2017, 58 : S8 - S8
  • [9] Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of theLEADERandSUSTAIN6 trials
    Verma, Subodh
    McGuire, Darren K.
    Bain, Stephen C.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    Mazer, C. David
    Monk Fries, Tea
    Pratley, Richard E.
    Rasmussen, Soren
    Vrazic, Hrvoje
    Zinman, Bernard
    Buse, John B.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (12): : 2487 - 2492
  • [10] Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
    Verma, Subodh
    Bain, Stephen C.
    Fries, Tea Monk
    Mazer, C. David
    Nauck, Michael A.
    Pratley, Richard E.
    Rasmussen, Soren
    Saevereid, Hans A.
    Zinman, Bernard
    Buse, John B.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (07): : 1745 - 1751
12345